Immatics Presents Clinical Activity of IMA203CD8 PRAME Cell Therapy in Hard-to-Treat ...

Immatics Presents Clinical Activity of IMA203CD8 PRAME Cell Therapy in Hard-to-Treat ...

One-time infusion of IMA203CD8 PRAME cell therapy in the ongoing Phase 1 dose escalation/dose expansion trial achieved anti-tumor activity in platinum-resistant ovarian cancer and in uterine cancer with a 63% objective response rate (ORR), 50% confirmed ORR (cORR), including four…

Phase 1 cell therapy shows 63% response in hard-to-treat gynecologic cancers

Heavily pretreated ovarian and uterine cancer patients saw 50% confirmed responses, plus 67% in synovial sarcoma, in Immatics’ Phase 1 IMA203CD8 trial.